Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma

1. Ruxolitinib may effectively treat parkinsonism arising from treatment with ciltacabtagene autoleucel in patients with multiple myeloma.

2. Two cases were detailed in a recent report, both of which showed successful control of parkinsonism with ruxolitinib.

3. Parkinsonism arising from ciltacabtagene autoleucel therapy has a distinct pathogenesis from Parkinson’s disease.

4. CAR T-cell therapy for multiple myeloma necessitates optimized therapy for potentially life-threatening complications, including parkinsonism.